Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.

ABSTRACT: We examined a large dataset of female metastatic breast cancers (MBCs) profiled with comprehensive genomic profiling (CGP) to identify the prevalence and distribution of immunotherapy responsiveness-associated biomarkers. DNA was extracted from 3831 consecutive MBCs: 1237 (ER^pos /HER2^neg ), 1953 ER^neg /HER2^amp , and 641 triple-negative breast cancer (TNBC). CGP was performed using the FoundationOne^® or FoundationOne^® CDx NGS assay. Tumor mutational burden (TMB) and microsatellite instability (MSI) were determined in a subset of cases. PD-L1 expression in immunocytes in a subset of cases was determined by immunohistochemistry using the companion diagnostic VENTANA PD-L1 SP142 Assay. The median age of the cohort was 54 years (

SUBMITTER: Sivapiragasam A 

PROVIDER: S-EPMC7826457 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature